PTEN loss confers resistance to anti-PD-1 therapy in NSCLC by increasing tumor infiltration of T regulatory cells

被引：3
|
作者：
Exposito, Francisco
Redrado, Miriam
Houry, Maeva
Hastings, Katherine
Molero-Abraham, Magdalena
Lozano, Teresa
Solorzano, Jose L.
Ortega, Julian Sanz
Andradas, Vera
Amat, Ramon
Redin, Esther
Leon, Sergio
Legarra, Naroa
Garcia, Javier
Serrano, Diego
Valencia, Karmele
Robles-Oteiza, Camila
Foggetti, Giorgia
Felip, Enriqueta
Lasarte, Juan J.
Paz-Ares, Luis
Zugazagoitia, Jon
Politi, Katerina
Montuenga, Luis M.
Calvo, Alfonso
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-1124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1124
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis
    Liling Wen
    Huanzi Lu
    Qiusheng Li
    Qunxing Li
    Shuqiong Wen
    Dikan Wang
    Xi Wang
    Juan Fang
    Jun Cui
    Bin Cheng
    Zhi Wang
    Journal of Experimental & Clinical Cancer Research, 38
  • [32] Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis
    Wen, Liling
    Lu, Huanzi
    Li, Qiusheng
    Li, Qunxing
    Wen, Shuqiong
    Wang, Dikan
    Wang, Xi
    Fang, Juan
    Cui, Jun
    Cheng, Bin
    Wang, Zhi
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
  • [33] How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC
    Chen, Li
    Jiang, Xiaoying
    Li, Yuanheng
    Zhang, Qiqi
    Li, Qing
    Zhang, Xiaoyan
    Zhang, Meng
    Yu, Qiongfang
    Gao, Dian
    CLINICAL IMMUNOLOGY, 2022, 237
  • [34] Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
    Andrea Botticelli
    Bruna Cerbelli
    Luana Lionetto
    Ilaria Zizzari
    Massimiliano Salati
    Annalinda Pisano
    Mazzuca Federica
    Maurizio Simmaco
    Marianna Nuti
    Paolo Marchetti
    Journal of Translational Medicine, 16
  • [35] Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
    Botticelli, Andrea
    Cerbelli, Bruna
    Lionetto, Luana
    Zizzari, Ilaria
    Salati, Massimiliano
    Pisano, Annalinda
    Federica, Mazzuca
    Simmaco, Maurizio
    Nuti, Marianna
    Marchetti, Paolo
    JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
  • [36] Tumor immune microenvironment characterization and response to anti-PD-1 therapy
    Santarpia, Mariacarmela
    Karachaliou, Niki
    CANCER BIOLOGY & MEDICINE, 2015, 12 (02) : 74 - 78
  • [37] Tumor immune microenvironment characterization and response to anti-PD-1 therapy
    Mariacarmela Santarpia
    Niki Karachaliou
    Cancer Biology & Medicine, 2015, (02) : 74 - 78
  • [38] Spatial proximity of CD8 T cells to tumor cells as an independent biomarker for response to anti-PD-1 therapy.
    Slagter, Maarten
    Rozeman, Elisa A.
    Ding, Huiwen
    Versluis, Judith M.
    Valenti, Mesele
    Peters, Dennis
    Broeks, Annegien
    van Rooijen, Charlotte
    Horlings, Hugo
    Haanen, John B. A. G.
    Hooijberg, Erik
    Wessels, Lodewyk F. A.
    Blank, Christian U.
    Schumacher, Ton N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Tumor immune microenvironment characterization and response to anti-PD-1 therapy
    Mariacarmela Santarpia
    Niki Karachaliou
    Cancer Biology & Medicine, 2015, 12 (02) : 74 - 78
  • [40] Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLC
    Bullock, Bonnie L.
    Kimball, Abigail K.
    Poczobutt, Joanna M.
    Neuwelt, Alexander J.
    Li, Howard Y.
    Johnson, Amber M.
    Kwak, Jeff W.
    Kleczko, Emily K.
    Kaspar, Rachael E.
    Wagner, Emily K.
    Hopp, Katharina
    Schenk, Erin L.
    Weiser-Evans, Mary C. M.
    Clambey, Eric T.
    Nemenoff, Raphael A.
    LIFE SCIENCE ALLIANCE, 2019, 2 (03)
12345